Organon

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Pfizer_shutterstock2

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Wall Street&#39;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

SPOK


When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector’s resilience, driven by aging populations and consistent demand for

High-Yield Healthcare: 3 Stocks With Strong Dividends

Scopri i 3 titoli sanitari che potrebbero crollare ad agosto

Long Ideas

ARQT

TMDX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4

Organon & Co

Origin Protocol - United States Dollar

OROGEN ROYALTIES INC by Orogen Royalties Inc.

Orogen Royalties Inc

ORGANA TECHS GRP INC by Organa Technologies Group, Inc.

Press Releases

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Reports Results for the Third Quarter Ended September 30, 2024

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Organon

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga